Study of Psychopathological Characteristics of Patient Smoking in Thoracic Oncology

NCT ID: NCT01955057

Last Updated: 2016-06-09

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 50 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2013-12-31
• Study Completion Date: 2016-06-30

Brief Summary

Persistent smoking after lung cancer has been the subject of medical, therapeutic and epidemiological publications for twenty years of research. Continued persistent smoking is all the more a problem for oncologists as there is evidence that smoking cessation, with lung cancer, gives therapeutic benefit. Quitting smoking can improve the response to treatments (chemotherapy, radiotherapy, surgery), quality of life and overall survival. However many patients refuse adhesion to tobacco cessation. Daily practice leads us to the hypothesis that adhesion differences aren't related to the denial of medical information, nor to resignation or to nicotine dependence. Patients who continue smoking seem to face a form of impossibility to wean. Cigarette seems to be felt as a part of their body in their narration and description of their body image.

Conditions

Smoking Cessation and Lung Cancer

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

Smokers with lung cancer

Research interviews

Intervention Type: BEHAVIORAL

Tests (Fagerström, Q-MAT, H.A.D.S, SCL 90-R)

Intervention Type: BEHAVIORAL

Projective methods (Thematic apperception Test, Rorschach)

Intervention Type: BEHAVIORAL

Carbon monoxide test

Intervention Type: BEHAVIORAL

Interventions

Research interviews

Intervention Type: BEHAVIORAL

Tests (Fagerström, Q-MAT, H.A.D.S, SCL 90-R)

Intervention Type: BEHAVIORAL

Projective methods (Thematic apperception Test, Rorschach)

Intervention Type: BEHAVIORAL

Carbon monoxide test

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• Men and women aged 18 years or older
• Patient affiliated to a social security system
• Patient who has signed and dated informed consent, written before all procedures related to the study
• Patient who has received the results of the previous mandatory medical examination
• Patient who has been diagnosed with lung cancer, regardless of the histological type of the cancer
• Patient who maintains an active smoking at the time of inclusion
• Patient who has smoked at least one cigarette in the previous year of inclusion
• Patient who is being treated for lung cancer (surgery, chemotherapy, radiotherapy) and not another form of cancer
• Tobacco consumer's only by smoke inhalation
• Tobacco consumer's or tobacco associated with cannabis

Exclusion Criteria

• Major patient under guardianship or curatorship or maintenance of justice
• Patient deprived of his liberty or in an emergency situation
• Patient with a Performance Statut(OMS) higher than 2 and/or with a psychiatric disorder like " schizophrenia and other psychotic disorders " (DSM IV)
• A palliative care patient
• Patient who began smoking during his diagnostic examination or after the diagnosis of cancer
• A pregnant or breastfeeding woman
• Patient in an exclusion period

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Strasbourg, France

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jonathan GRAFFI

Role: PRINCIPAL_INVESTIGATOR

Hôpitaux Universitaires de Strasbourg

Locations

Nouvel Hôpital Civil, Service de pneumologie, Unité de cancérologie thoracique, Hôpitaux Universitaires de Strasbourg

Strasbourg, , France

Countries

France

Other Identifiers

5579

Identifier Type: -

Identifier Source: org_study_id